我国口咽癌与HPV的关系

doi:10.3760/cma.j.issn.1673-422X.2020.03.007

摘要/Abstract

摘要：

口咽癌是常见的头颈部恶性肿瘤之一,据流行病学研究显示,我国口咽癌发病率及死亡率正逐年上升。除烟酒外,人乳头瘤病毒(HPV)现已被证实是口咽癌病因之一,我国学者也证实了我国口咽癌与HPV的相关性,但HPV感染在我国口咽癌患者中的占比仍需更大样本的数据统计。目前,国内外研究都表明HPV相关性口咽癌患者的疗效及预后均较好,该类患者的治疗模式为目前研究热点。另外,HPV疫苗、人群口咽/口腔部位HPV感染的筛查为该类疾病的预防提供了进一步的研究方向。

关键词: 口咽肿瘤, 中国, 人乳头瘤病毒16, 综合疗法, 乳头状瘤病毒疫苗

Abstract:

Oropharyngeal cancer (OPC) is one of the head and neck cancers. According to epidemiological data, the incidence and mortality of OPC in China are increasing. In addition to tobacco and alcohol, human papillomavirus (HPV) has been proved to be one of the causes of OPC. Chinese scholars have also confirmed the correlation between HPV and OPC in China, but the proportion of HPV infection in OPC in China still needs a larger sample. Because lots of studies have shown that the efficacy and prognosis of HPV-related OPC are better, the treatment of this type of patients is the current research hotspot. Meanwhile, HPV vaccine and the screening method for HPV infection in the oropharynx or oral cavity of the population deserve further research.

Key words: Oropharyngeal neoplasms, China, Human papillomavirus 16, Combined modality therapy, Papillomavirus vaccines

郑歆, 陈晓品. 我国口咽癌与HPV的关系[J]. 国际肿瘤学杂志, 2020, 47(3): 164-168.

Zheng Xin, Chen Xiaopin. Relationship between HPV and oropharyngeal cancer in China[J]. Journal of International Oncology, 2020, 47(3): 164-168.

参考文献 39

[1]	Gillison ML, Chaturvedi AK, Anderson WF , et al. Epidemiology of human papillomavirus-positive head and neck squamous cell carcinoma[J]. J Clin Oncol, 2015,33(29):3235-3242. DOI: 10.1200/JCO.2015.61.6995. doi: 10.1200/JCO.2015.61.6995
[2]	Westra WH, Lewis JS Jr . Update from the 4th edition of the world health organization classification of head and neck tumours: Oropharynx[J]. Head Neck Pathol, 2017,11(1):41-47. DOI: 10.1007/s12105-017-0793-2. doi: 10.1007/s12105-017-0793-2
[3]	Liu J, Yang XL, Zhang SW , et al. Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study[J]. Cancer Commun (Lond), 2018,38(1):75. DOI: 10.1186/s40880-018-0345-5.
[4]	Liu J, Yang XL, Zhang SW , et al. Correction to: Incidence, mortality, and temporal patterns of oropharyngeal cancer in China: a population-based study[J]. Cancer Commun (Lond), 2019,39(1):6. DOI: 10.1186/s40880-019-0352-1.
[5]	Zhang LW, Li J, Cong X , et al. Incidence and mortality trends in oral and oropharyngeal cancers in China, 2005-2013[J]. Cancer Epidemiol, 2018,57:120-126. DOI: 10.1016/j.canep.2018.10.014. doi: 10.1016/j.canep.2018.10.014
[6]	Vokes EE, Agrawal N, Seiwert TY . HPV associated head and neck cancer[J]. J Natl Cancer Inst, 2015,107(12):djv344. DOI: 10.1093/jnci/djv344. doi: 10.1093/jnci/djv344
[7]	李武, 赵九洲, 王志中 . 不同方法检测口咽鳞癌中高危型HPV的感染情况分析[J]. 肿瘤学杂志, 2018,24(6):568-572. DOI: 10.11735/j.issn.1671-170X.2018.06.B008.
[8]	Paver EC, Currie AM, Gupta R , et al. Human papilloma virus related squamous cell carcinomas of the head and neck: diagnosis, clinical implications and detection of HPV[J]. Pathology, 2020,52(2):179-191. DOI: 10.1016/j.pathol.2019.10.008. doi: 10.1016/j.pathol.2019.10.008
[9]	中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)头颈肿瘤诊疗指南2019[M]. 北京: 人民卫生出版社, 2019.
[10]	张永侠, 刘明波, 黄辉 , 等. 第七版与第八版美国癌症联合会TNM分期对口咽癌预后生存的分析比较[J]. 临床耳鼻咽喉头颈外科杂志, 2019(7):586-590. DOI: 10.13201/j.issn.1001-1781.2019.07.003.
[11]	Lam EW, Chan JY, Chan AB , et al. Prevalence, clinicopathological characteristics, and outcome of human papillomavirus-associated oropharyngeal cancer in southern Chinese patients[J]. Cancer Epidemiol Biomarkers Prev, 2016,25(1):165-173. DOI: 10.1158/1055-9965.EPI-15-0869. doi: 10.1158/1055-9965.EPI-15-0869
[12]	Chor JS, Vlantis AC, Chow TL , et al. The role of human papillomavirus in head and neck squamous cell carcinoma: a case control study on a southern Chinese population[J]. J Med Virol, 2016,88(5):877-887. DOI: 10.1002/jmv.24405. doi: 10.1002/jmv.v88.5
[13]	Ni G, Huang K, Luan Y , et al. Human papillomavirus infection among head and neck squamous cell carcinomas in southern China[J]. PLoS One, 2019,14(9):e0221045. DOI: 10.1371/journal.pone.0221045. doi: 10.1371/journal.pone.0221045
[14]	Wang Z, Xia RH, Ye DX , et al. Human papillomavirus 16 infection and TP53 mutation: two distinct pathogeneses for oropharyngeal squamous cell carcinoma in an eastern Chinese population[J]. PLoS One, 2016,11(10):e0164491. DOI: 10.1371/journal.pone.0164491. doi: 10.1371/journal.pone.0164491
[15]	Cheng NM, Chang JT, Huang CG , et al. Prognostic value of pretreatment ¹⁸F-FDG PET/CT and human papillomavirus type 16 testing in locally advanced oropharyngeal squamous cell carcinoma [J]. Eur J Nucl Med Mol Imaging, 2012,39(11):1673-1684. DOI: 10.1007/s00259-012-2186-9. doi: 10.1007/s00259-012-2186-9
[16]	黄辉, 张彬, 陈汶 , 等. 口咽部鳞状细胞癌人乳头状瘤病毒感染预后初步分析[J]. 中华耳鼻咽喉头颈外科杂志, 2012,47(3):207-211. DOI: 10.3760/cma.j.issn.1673-0860.2012.03.007.
[17]	费继敏, 武要洪, 曾汶 , 等. 口咽鳞癌中HPV感染与血管生成的关系[J]. 现代肿瘤医学, 2016,24(04):41-44. DOI: 10.3969/j.issn.1672-4992.2016.04.010.
[18]	Ma X, Sheng S, Wu J , et al. LncRNAs as an intermediate in HPV16 promoting myeloid-derived suppressor cell recruitment of head and neck squamous cell carcinoma[J]. Oncotarget, 2017,8(26):42061-42075. DOI: 10.18632/oncotarget.14939. doi: 10.18632/oncotarget.v8i26
[19]	Wang F, Zhang H, Xue Y , et al. A systematic investigation of the association between HPV and the clinicopathological parameters and prognosis of oral and oropharyngeal squamous cell carcinomas[J]. Cancer Med, 2017,6(5):910-917. DOI: 10.1002/cam4.1045. doi: 10.1002/cam4.1045
[20]	Meng HX, Miao SS, Chen K , et al. Association of p16 as prognostic factors for oropharyngeal cancer: evaluation of p16 in 1470 patients for a 16 year study in northeast China[J]. Biomed Res Int, 2018,2018:9594568. DOI: 10.1155/2018/9594568.
[21]	吴蒙, 孙玉满, 刘宏侠 , 等. 唐山地区EBV及HPV感染与口咽鳞癌预后相关性分析[J]. 中华肿瘤防治杂志, 2015,22(18):1422-1427. DOI: 10.16073/j.cnki.cjcpt.2015.18.00.
[22]	Mujtaba H, Wang Y, Duan Y , et al. Human papillomavirus in tonsillectomy specimen from China and Pakistan-prevalence and genotype distribution[J]. Pathol Res Pract, 2018,214(10):1713-1718. DOI: 10.1016/j.prp.2018.08.032. doi: 10.1016/j.prp.2018.08.032
[23]	Guo L, Yang F, Yin Y , et al. Prevalence of human papillomavirus type-16 in head and neck cancer among the Chinese population: a meta-analysis[J]. Front Oncol, 2018,8:619. DOI: 10.3389/fonc.2018.00619. doi: 10.3389/fonc.2018.00619
[24]	Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer working group. Chinese Society of Clinical Oncology (CSCO) diagnosis and treatment guidelines for head and neck cancer 2018 (English version)[J]. Chin J Cancer Res, 2019,31(1):84-98. DOI: 10.21147/j.issn.1000-9604.2019.01.05. doi: 10.21147/j.issn.1000-9604.2019.01.05
[25]	Coordes A, Lenz K, Qian X , et al. Meta-analysis of survival in patients with HNSCC discriminates risk depending on combined HPV and p16 status[J]. Eur Arch Otorhinolaryngol, 2016,273(8):2157-2169. DOI: 10.1007/s00405-015-3728-0. doi: 10.1007/s00405-015-3728-0
[26]	Fakhry C, Zhang Q, Gillison ML , et al. Validation of NRG oncology/RTOG-0129 risk groups for HPV-positive and HPV-negative oropharyngeal squamous cell cancer: implications for risk-based therapeutic intensity trials[J]. Cancer, 2019,125(12):2027-2038. DOI: 10.1002/cncr.32025. doi: 10.1002/cncr.32025
[27]	Fakhry C, Zhang Q, Nguyen-Tan PF , et al. Development and validation of nomograms predictive of overall and progression-free survival in patients with oropharyngeal cancer [J]. J Clin Oncol, 2017,35(36):4057-4065. DOI: 10.1200/JCO.2016.72.0748. doi: 10.1200/JCO.2016.72.0748
[28]	Hegde JV, Shaverdian N, Daly ME , et al. Patient-reported quality-of-life outcomes after de-escalated chemoradiation for human papillomavirus-positive oropharyngeal carcinoma: findings from a phase 2 trial[J]. Cancer, 2018,124(3):521-529. DOI: 10.1002/cncr.30954. doi: 10.1002/cncr.v124.3
[29]	Marur S, Li S, Cmelak AJ , et al. E1308: phase Ⅱ trial of induction chemotherapy followed by reduced-dose radiation and weekly cetuximab in patients with HPV-associated resectable squamous cell carcinoma of the Oropharynx- ECOG-ACRIN Cancer Research Group[J]. J Clin Oncol, 2017,35(5):490-497. DOI: 10.1200/JCO.2016.68.3300.
[30]	Chen AM, Felix C, Wang PC , et al. Reduced-dose radiotherapy for human papillomavirus-associated squamous-cell carcinoma of the oropharynx: a single-arm, phase 2 study[J]. Lancet Oncol, 2017,18(6):803-811. DOI: 10.1016/S1470-2045(17)30246-2. doi: 10.1016/S1470-2045(17)30246-2
[31]	Chera BS, Amdur RJ, Tepper JE , et al. Mature results of a prospective study of deintensified chemoradiotherapy for low-risk human papillomavirus-associated oropharyngeal squamous cell carcinoma[J]. Cancer, 2018,124(11):2347-2354. DOI: 10.1002/cncr.31338. doi: 10.1002/cncr.v124.11
[32]	Wang HF, Wang SS, Tang YJ , et al. The double-edged sword-how human papillomaviruses interact with immunity in head and neck cancer[J]. Front Immunol, 2019,10:653. DOI: 10.3389/fimmu.2019.00653. doi: 10.3389/fimmu.2019.00653
[33]	Gillison ML, Trotti AM, Harris J , et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial[J]. Lancet, 2019,393(10166):40-50. DOI: 10.1016/S0140-6736(18)32779-X. doi: 10.1016/S0140-6736(18)32779-X
[34]	Mehanna H, Robinson M, Hartley A , et al. Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial[J]. Lancet, 2019,393(10166):51-60. DOI: 10.1016/S0140-6736(18)32752-1. doi: 10.1016/S0140-6736(18)32752-1
[35]	Sias C, Salichos L, Lapa D , et al. Alpha, beta, gamma human papillomaviruses (HPV) detection with a different sets of primers in oropharyngeal swabs, anal and cervical samples[J]. Virol J, 2019,16(1):27. DOI: 10.1186/s12985-019-1132-x.
[36]	Zhang C, Liu F, Pan Y , et al. Incidence and clearance of oral human papillomavirus infection: a population-based cohort study in rural China[J]. Oncotarget, 2017,8(35):59831-59844. DOI: 10.18632/oncotarget.16306. doi: 10.18632/oncotarget.v8i35
[37]	Wong MCS, Vlantis AC, Liang M , et al. Prevalence and epidemiologic profile of oral infection with alpha, beta, and gamma papillomaviruses in an Asian Chinese population[J]. J Infect Dis, 2018,218(3):388-397. DOI: 10.1093/infdis/jiy160. doi: 10.1093/infdis/jiy160
[38]	Wang Z, Li F, Rufo J , et al. Acoustofluidic salivary exosome isolation: a liquid biopsy compatible approach for human papillomavirus-associated oropharyngeal cancer detection[J]. J Mol Diagn, 2020,22(1):50-59. DOI: 10.1016/j.jmoldx.2019.08.004. doi: 10.1016/j.jmoldx.2019.08.004
[39]	Herrero R, Quint W, Hildesheim A , et al. Reduced prevalence of oral human papillomavirus (HPV) 4 years after bivalent HPV vaccination in a randomized clinical trial in Costa Rica[J]. PLoS One, 2013,8(7):e68329. DOI: 10.1371/journal.pone.0068329. doi: 10.1371/journal.pone.0068329